Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11951590 | 0.84 | TDP1 (0.71) | TDP1MEN1KMT2AHTTLMNA | |
| SCHEMBL10824702 | 0.83 | KMT2A (0.59) | TDP1MEN1KMT2AHTTLMNA | |
| SCHEMBL22579845 | 0.82 | DRD2 (0.48) | TDP1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL10593412 | 0.81 | MEN1 (0.62) | TDP1MEN1KMT2AHTTLMNA | |
| SCHEMBL14579974 | 0.81 | MEN1 (0.62) | TDP1MEN1KMT2AHTTLMNA | |
| SCHEMBL21096683 | 0.80 | KCNA3 (0.54) | TDP1LMNAMAPK1 | |
| SCHEMBL16870165 | 0.80 | KMT2A (0.53) | TDP1MEN1KMT2AHTTLMNA | |
| SCHEMBL13568875 | 0.79 | MEN1 (0.61) | TDP1MEN1KMT2AHTTLMNA | |
| SCHEMBL6473012 | 0.78 | MEN1 (0.54) | TDP1MEN1KMT2AHTTLMNA | |
| SCHEMBL5018762 | 0.78 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | TLR9, STING1, TLR3 | TDP1 218/4885MEN1 1123/4885KMT2A 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.